(Q37936321)

25 August 2017

1 reference

title

The management of chronic hepatitis B in Asian Americans (English)

1 reference

25 August 2017

1 reference

1 reference

4

Kris V Kowdley

1 reference

25 August 2017

Myron J Tong

1

1 reference

25 August 2017

Calvin Q Pan

2

1 reference

25 August 2017

Hie-Won Hann

3

1 reference

25 August 2017

Steven-Huy B Han

5

1 reference

25 August 2017

Albert D Min

6

1 reference

25 August 2017

Truong-Sinh Leduc

7

1 reference

25 August 2017

language of work or name

1 reference

21 September 2011

1 reference

Digestive Diseases and Sciences

25 August 2017

1 reference

25 August 2017

56

1 reference

25 August 2017

11

1 reference

25 August 2017

3143-3162

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-011-1841-5

25 August 2017

0 references

cites work

Chronic hepatitis B virus infection in Asian countries

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Current status of liver diseases in Korea: hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis B viral factors and clinical outcomes of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Natural history of hepatitis B and C virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis B virus and primary hepatocellular carcinoma: family studies in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatocellular carcinoma in the Asia pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis B virus infection: epidemiology and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

How to predict HCC development in patients with chronic B viral liver disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis B virus: inactive carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Management of hepatitis B: summary of a clinical research workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis B virus-related cirrhosis: natural history and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Natural history of chronic hepatitis B REVEALed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Chronic hepatitis B in Asia-new insights from the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Long-term outcome of chronic hepatitis B based on histological grade and stage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Chronic hepatitis B and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: univariate and multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

A proposed, evidence-based approach to the treatment of chronic Hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Natural history and prognosis of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Natural history of chronic hepatitis B virus infection and long-term outcome under treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Side effects of long-term oral antiviral therapy for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Primary infection with a lamivudine-resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Lamivudine therapy in the treatment of chronic hepatitis B with acute exacerbation during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis D: Scenario in the Asia-Pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis B and human immunodeficiency virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Hepatitis B viral factors in HBeAg-Negative carriers with persistently normal serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1841-5

Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues

21 January 2018

1 reference

12 December 2020

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B

1 reference

12 December 2020

Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab

1 reference

12 December 2020

Hepatocellular Carcinoma and Hepatitis B Virus

1 reference

12 December 2020

Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

1 reference

12 December 2020

Hepatitis B virus infection in Asian Americans

1 reference

12 December 2020

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

1 reference

12 December 2020

Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.

1 reference

12 December 2020

Perinatal transmission of hepatitis B virus: an Australian experience

1 reference

12 December 2020

Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers

1 reference

12 December 2020

A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults

1 reference

12 December 2020

Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase

1 reference

12 December 2020

A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection

1 reference

12 December 2020

Recommendations for identification and public health management of persons with chronic hepatitis B virus infection

1 reference

12 December 2020

The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.

1 reference

12 December 2020

10.1007/S10620-011-1841-5

Identifiers

DOI

1 reference

25 August 2017

1 reference